Celcuity Inc. (CELC)
$
106.02
-8.79 (-8.29%)
Key metrics
Financial statements
Free cash flow per share
-2.9221
Market cap
5.1 Billion
Price to sales ratio
0
Debt to equity
1.9430
Current ratio
10.5467
Income quality
0.8658
Average inventory
0
ROE
-2.0317
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Celcuity Inc., a clinical stage biotechnology company focused on developing molecularly targeted therapies for cancer patients in the United States, reported an income before tax of -$177,042,000.00 showcasing its pre-tax profitability. Despite this positive indication, the company reported a net loss of -$177,042,000.00 indicating challenges in its operations. The earnings per share (EPS) is reported at -$3.78 which highlights the company's profitability on a per-share basis. Additionally, the company reported depreciation and amortization expenses of $167,000.00 reflecting the wear and tear of its assets. The income before tax ratio stands at 0.00 reflecting the pre-tax margin. Celcuity's CELsignia diagnostic platform allows for the identification of specific abnormal cellular processes in patients’ cancer using their living tumor cells, enabling targeted therapy selection. Among its drug candidates, Gedatolisib selectively targets various class I isoforms of PI3K and mammalian target of rapamycin, particularly focusing on hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also advancing the CELsignia MP test, a qualitative laboratory-developed test to measure HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Furthermore, Celcuity has a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Founded in 2011 and headquartered in Minneapolis, Minnesota, the company operates within a crucial and transformative landscape of cancer treatment. In terms of its market positioning, the stock is affordable at $51.88 making it suitable for budget-conscious investors. With a low average trading volume of 703,445.00 the stock indicates lower market activity, suggesting a potentially less volatile investment environment. With a market capitalization of $5,124,654,071.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor shaping the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth, providing promising avenues for investment as it continues to develop its targeted therapies and diagnostic platforms.
Is Celcuity Inc. (CELC) a good investment?
Investing in Celcuity Inc. (CELC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Celcuity Inc. (CELC)'s stock forecast?
Analysts predict Celcuity Inc. stock to fluctuate between $7.58 (low) and $120.32 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Celcuity Inc.'s market capitalization?
As of 2026-03-27, Celcuity Inc.'s market cap is $5,124,654,071, based on 48,336,673 outstanding shares.
How does Celcuity Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Celcuity Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Celcuity Inc. (CELC) stock?
To buy Celcuity Inc. (CELC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CELC. Place an order (Market, Limit, etc.).
What is the best time to invest in Celcuity Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Celcuity Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.78 | Growth: 33.57%.
Where can I find Celcuity Inc.'s investor relations reports?
Visit https://www.celcuity.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Celcuity Inc.?
You can explore historical data from here
What is the all-time high and low for Celcuity Inc. stock?
All-time high: $120.32 (2026-01-27) | All-time low: $4.81 (2022-05-17).
What are the key trends affecting Celcuity Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.
seekingalpha.com
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
seekingalpha.com
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
globenewswire.com
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) PIK3CA WT advanced breast cancer (“ABC”), following progression on or after treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
seekingalpha.com
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
fool.com
Acquired 135,000 shares of Celcuity; estimated trade size of $11.10 million based on quarterly average pricing Quarter-end position value rose by $18.00 million, reflecting both trading and price appreciation Trade represented a 2.4% increase relative to Boxer Capital's reportable AUM Post-trade, Boxer Capital held 225,000 Celcuity shares valued at $22.44 million Celcuity now accounts for 4.9% of AUM, outside Boxer Capital's top five holdings
seekingalpha.com
The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.
fool.com
Perceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing. Meanwhile, the quarter-end position value rose by $169.16 million, reflecting both share additions and price movements.
seekingalpha.com
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
zacks.com
Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.
See all news
